Alternative Methods and Strategies to Reduce, Refine, and Replace Animal Use for Veterinary Vaccine Post-Licensing Safety Testing: State of The Science and Future Directions

Procedia in Vaccinology

Volumn 5, Issue , 2011, Pages 106-119

  Kulpa Eddy, Jodie ^a   Srinivas, Geetha ^a   Halder, Marlies ^b   Brown, Karen ^c   Draayer, Hans ^d   Galvin, Jeffrey ^d   Claassen, Ivo ^e   Gifford, Glen ^f   Woodland, Ralph ^g   Doelling, Vivian ^h   Jones, Brett ^h   Stokes, William S ⁱ  

^a UNITED STATES DEPARTMENT OF AGRICULTURE   (United States)

^b JOINT RESEARCH CENTRE   (Italy)

^c Pair O'Docs Enterprises   (United States)

^d ZOETIS   (United States)

^e WAGENINGEN UNIVERSITY   (Netherlands)

^f CANADIAN FOOD INSPECTION AGENCY   (Canada)

^g Veterinary Medicines Directorate   (United Kingdom)

^h INTEGRATED LABORATORY SYSTEMS   (United States)

ⁱ NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Alternative methods; ICCVAM; Reduction; Refinement; Replacement; Vaccine safety testing; Veterinary vaccines

Indexed keywords

DNA VACCINE; LIVE VACCINE; NEWCASTLE DISEASE VACCINE; RABIES VACCINE; VACCINE;

ANIMAL HEALTH; ANIMAL TESTING REDUCTION; ANIMAL TESTING REFINEMENT; ANIMAL TESTING REPLACEMENT; ARTICLE; BIRD DISEASE; CLOSTRIDIUM; DRUG SCREENING; HUMAN; IN VIVO STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIMARY CELL CULTURE; PRIORITY JOURNAL; RABIES; VACCINE PRODUCTION; WORKSHOP;

EID: 84555190338     PISSN: None     EISSN: 1877282X     Source Type: Journal    
DOI: 10.1016/j.provac.2011.10.007     Document Type: Article

References (65)

1. Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM). The NICEATM-ICCVAM five-year plan (2008-2012): a plan to advance alternative test methods of high scientific quality to protect and advance the health of people, animals, and the environment. National Institute of Environmental Health Sciences, 2008. NIH Publication No. 08-6410. http://iccvam.niehs.nih.gov/docs/5yearplan.htm.
2. Stokes WS, Kulpa-Eddy J, McFarland RM. Introduction and summary of the international workshop on alternative methods to reduce, refine, and replace the use of animals in vaccine potency and safety testing: state of the science and future directions. Proc Vaccinol 2011 (current issue).
3. McFarland R, Verthelyi D, Casey W, Arciniega J, Isbrucker R, Schmitt M, Finn T, Descamps J, Horiuchi Y, Sesardic D, Stickings P, Johnson NW, Lipscomb E, Allen D. Non-animal replacement methods for human vaccine potency testing: state-of-the-science and future directions. Proc Vaccinol 2011 (current issue).
4. Kulpa-Eddy J, Srinivas G, Halder M, Hill R, Brown K, Roth J, Draayer H, Galvin J, Claassen I, Gifford G, WoodlandR, Doelling V, Jones B, Stokes WS. Non-animal replacement methods for veterinary vaccine potency testing: state-of-the-science and future directions. Proc Vaccinol 2011 (current issue).
5. Casey W, Schmitt M, McFarland R, Isbrucker R, Levis R, Arciniega J, Descamps J, Finn T, Hendriksen C, Horiuchi Y, Keller J, Kojima H, Sesardic D, Stickings P, Johnson NW, Lipscomb E, Allen D. Improving animal welfare and reducing and refining animal use for human vaccine potency testing: state-of-the-science and future directions. Proc Vaccinol 2011 (current issue).
6. Stokes WS, Brown K, Kulpa-Eddy J, Srinivas G, Halder M, Draayer H, Galvin J, Claassen I, Gifford G, Woodland R, Doelling V, Jones B. Improving animal welfare and reducing animal use for veterinary vaccine potency testing: state-of-the-science and future directions. Proc Vaccinol 2011 (current issue).
7. Isbrucker R, Levis R, Casey W, McFarland R, Schmitt M, Arciniega J, Descamps J, Finn T, Hendriksen C, Horiuchi Y, Keller J, Kojima H, Sesardic D, Stickings P, Johnson NW, Allen D. Alternative methods and strategies to reduce, refine, and replace animal use for human vaccine post-licensing safety testing: state of the science and future directions. Proc Vaccinol 2011 (current issue).
8. Kulpa-Eddy J, Srinivas G, Halder M, Hill R, Brown K, Draayer H, Galvin J, Claassen I, Gifford G, Woodland R, Doelling V, Jones B, Stokes WS. Alternative methods and strategies to reduce, refine, and replace animal use for veterinary vaccine post-licensing safety testing: state of the science and future directions. Proc Vaccinol 2011 (current issue).
9. Roth J. Veterinary vaccines and their importance to animal health and public health. Proc Vaccinol 2011 (current issue).
10. Schuchat A. Human vaccines and their importance to public health. Proc Vaccinol 2011 (current issue).
11. Finn T. U.S. FDA Requirements for human vaccine safety and potency testing. Proc Vaccinol 2011 (current issue).
12. Hill RE. USDA requirements for veterinary vaccine safety and potency testing. Proc Vaccinol 2011 (current issue).
13. Isbrucker R, Sontakke S, Smith D. Health Canada's human vaccine lot release program: impact on the 3Rs. Proc Vaccinol 2011 (current issue).
14. Woodland R. European regulatory requirements for veterinary vaccine safety and potency testing and recent progress toward reducing animal use. Proc Vaccinol 2011 (current issue).
15. Horiuchi Y, Ochiai M, Kataoka M, Yamamoto A, Yuen C-T, Asokanathan C, Corbel M, Kurata T, Xing D. Strategic approaches for developing alternative tests for safety and potency of vaccines. Proc Vaccinol 2011 (current issue).
16. Shin J, Lei D, Conrad C, Knezevic I, Wood D. International Regulatory Requirements for Vaccine Safety and Potency Testing: A WHO perspective. Proc Vaccinol 2011 (current issue).
17. Draayer H. Overview of currently approved veterinary vaccine potency testing methods and methods in development that do not require animal use. Proc Vaccinol 2011 (current issue).
18. Claassen I. Case study of development, validation, and acceptance of a non-animal method for assessing veterinary vaccine potency. Proc Vaccinol 2011 (current issue).
19. Levis R. Overview of the current status of human vaccine potency testing methods that replace animals. Presented at: International Workshop on Alternative Methods to Reduce, Refine, and Replace the Use of Animals in Vaccine Potency and Safety Testing: State of the Science and Future Directions. NICEAM. Bethesda, MD. September 2010. Available at: http://iccvam.niehs.nih.gov/meetings/BiologicsWksp-2010/BiologicsWksp-present.htm.
20. Descamps J, et al. A Case study of development, validation, and acceptance of a non-animal method for assessing human vaccine potency. Proc Vaccinol 2011 (current issue).
21. Keller JE. Overview of currently approved serological methods with a focus on diphtheria and tetanus toxoid potency testing. Proc Vaccinol 2011 (current issue).
22. Srinivas G. Refinement alternatives for veterinary vaccine potency testing: overview of currently approved serological methods. Presented at: International Workshop on Alternative Methods to Reduce, Refine, and Replace the Use of Animals in Vaccine Potency and Safety Testing: State of the Science and Future Directions. NICEAM. Bethesda, MD. September 2010. Available at: http://iccvam.niehs.nih.gov/meetings/BiologicsWksp-2010/BiologicsWksp-present.htm.
23. Stickings P, Rigsby P, Coombes L, Hockley J, Tierney R, Sesardic D. Animal refinement and reduction: alternative approaches for potency testing of diphtheria and tetanus vaccines. Proc Vaccinol 2011 (current issue).
24. Arciniega JL, Domínguez-Castillo RI. Development and validation of serological methods for human vaccine potency testing: case study of an anthrax vaccine. Proc Vaccinol 2011 (current issue).
25. Hendriksen CFM. Humane endpoints in vaccine potency testing. Proc Vaccinol 2011 (current issue).
26. Kulpa-Eddy J, Srinivas G. Examples of approaches to reducing animal numbers in vaccine potency testing. Proc Vaccinol 2011 (current issue).
27. Kulpa-Eddy J, Dusek D. Application of the consistency approach in the United States to reduce animal use in vaccine potency testing. Proc Vaccinol 2011 (current issue).
28. Gifford G, Agrawal P, Hutchings D, Yarosh O. Veterinary vaccine post-licensing safety testing: overview of current regulatory requirements and accepted alternatives. Proc Vaccinol 2011 (current issue).
29. Arciniega JL, Corvette L, Hsu H, Lynn F, Romani T, Dobbelaer R. Target alternative vaccine safety testing strategies for Pertussis toxin. Proc Vaccinol 2011 (current issue).
30. Rubin SA. Toward replacement of the monkey neurovirulence test in vaccine safety testing. Proc Vaccinol 2011 (current issue).
31. United States Public Law 430 of 1913 and Public Law 99-198 (1985 amendments to the Virus-Serum-Toxin Act); Title 21 U.S. Code, Chapter 5 §§ 151 et. seq.
32. United States Department of Agriculture. Code of Federal Regulations, Title 9, Animal and Animal Products. Part 113-Standard Requirements. http://law.justia.com/us/cfr/title09/9-1.0.1.5.50.html.
33. United States Department of Agriculture. Code of Federal Regulations, Title 9, Animal and Animal Products. Part 113-Standard Requirements. Section 133.33. Mouse Safety Tests. http://law.justia.com/us/cfr/title09/9-1.0.1.5.50.0.69.19.html.
34. United States Department of Agriculture. Code of Federal Regulations, Title 9, Animal and Animal Products. Part 113-Standard Requirements. Section 113.38. Guinea Pig Safety Test. http://law.justia.com/us/cfr/title09/9-1.0.1.5.50.0.69.24.html.
35. European Pharmacopoeia Monograph 01/2008:0062. Vaccines for Veterinary Use. 6th ed. Strasbourg, France; European Department for the Quality of Medicine within the Council of Europe. 2008.
36. Metz B, Hendriksen C, Jiskoot W, Kersten G. Reduction of animal use in human vaccine quality control: opportunities and problems. Vaccine 2002;20:2411-2430.
37. Hendriksen C. Refinement, reduction, and replacement of animal use for regulatory testing: Current best scientific practices for the evaluation of safety and potency of biologicals. ILAR Journal 2002; 43 Suppl:S43-48.
38. Hendriksen C, Arciniega JL, Bruckner L, Chevalier M, Coppens E, Descamps J, Duchene M, Dusek DM, Halder M, Kreeftenberg H, Maes A, Redhead K, Ravetkar SD, Spieser J-M, Swam H. The consistency approach for the quality control of vaccines. Biologicals 2008;36:73-77.
39. Office International des Epizooties. The role of official bodies in the international regulation of veterinary biologicals. In: Manual of Standards for Diagnostic Tests and Vaccines, Fourth Ed. Paris, France, Office International des Epizooties, 2000: pp.63-73.
40. European Pharmacopoeia Monograph 01/2008:20625. Avian Live Virus Vaccines: Tests for Extraneous Agents in Batches of Finished Product. 6th ed. Strasbourg, France; European Department for the Quality of Medicine within the Council of Europe. 2008.
41. Bruckner L, Bongers J, Castle P, Flore PH, Guittet M, Halder M, Jungback C, Le Gros FX, Tollis M, Nair VK, Wilhelm M, Zeegers J, Zigterman G. Three Rs approaches in the production and quality control of avian vaccines. The report and recommendations of ECVAM workshop 41. ATLA 2000; 28:241-258.
42. Ottiger HP. Use of PCR for extraneous agent testing in avian vaccines. In: Advancing Science and Eliminating the Use of Laboratory Animals for Development and Control of Vaccines and Hormones. Basel, Karger; Dev Biol 2002;111:23-26.
43. Ottiger HP. Monitoring veterinary vaccines for contaminating viruses. In: Vannier P, Espeseth D, editors. New Diagnostic Technology: Applications in Animal Health and Biologics Controls. Basel, Karger, Dev Biol 2006;126:309-319.
44. Ottiger HP. Development, standardization and assessment of PCR systems for purity testing of avian vaccines. Biologicals 2010;38:381-388.
45. Bruckner L, Cussler K, Halder M, Barrat J, Castle P, Duchow K, Gatewood DM, Gibert R, Groen J, Knapp B, Levis R, Milne C, Parker S, Stünkel K, Visser N, Volkers P. Three Rs approaches in the quality control of inactivated rabies vaccines. The report and recommendations of ECVAM Workshop 48. ALTA 2003;31:429-454.
46. United States Department of Agriculture. Code of Federal Regulations, Title 9, Animal and Animal Products. Part 113-Standard Requirements. Section 113.209. Rabies Vaccine, Killed Virus. http://law.justia.com/us/cfr/title09/9-1.0.1.5.50.0.73.81.html.
47. Office International des Epizooties. Rabies. In Manual of Standards for Diagnostic Tests and Vaccines, 4th edn, Paris, France. 2000. pp. 276-291.
48. Blum S, Braunschweiger M, Kramer B, Duchow K, Cussler K. Inactivation test for rabies vaccines: A comparison of test results from in vivo and in vitro methods. Pharmeuropa Special Issue, Proceedings Biologicals Beyond 2000, 2001;390.
49. European Pharmacopoeia. Monograph 01/2010:0451. Rabies Vaccine (Inactivated) for Veterinary Use. 7th ed. Strasbourg, France: European Department for the Quality of Medicines within the Council of Europe; 2010.
50. United States Department of Agriculture. Code of Federal Regulations, Title 9, Animal and Animal Products. Part 113-Standard Requirements. Section 113.204. Mink Enteritis Vaccine, Killed Virus. http://law.justia.com/us/cfr/title09/9-1.0.1.5.50.0.73.76.html.
51. United States Department of Agriculture. Code of Federal Regulations, Title 9, Animal and Animal Products. Part 113-Standard Requirements. Section 113.205. Newcastle Disease Vaccine, Killed Virus. http://law.justia.com/us/cfr/title09/9-1.0.1.5.50.0.73.77.html.
52. United States Department of Agriculture. Code of Federal Regulations, Title 9, Animal and Animal Products. Part 113-Standard Requirements. Section 113.215. Bovine Virus Diarrhea Vaccine, Killed Virus. http://law.justia.com/us/cfr/title09/9-1.0.1.5.50.0.73.87.html.
53. United States Department of Agriculture. Code of Federal Regulations, Title 9, Animal and Animal Products. Part 113-Standard Requirements. Section 113.201. Canine Distemper Vaccine, Killed Virus. http://law.justia.com/us/cfr/title09/9-1.0.1.5.50.0.73.73.html.
54. United States Department of Agriculture. Code of Federal Regulations, Title 9, Animal and Animal Products. Part 113-Standard Requirements. Section 113.316. Canine Parainfluenza Vaccine. http://cfr.vlex.com/vid/316-canine-parainfluenza-vaccine-19609135.
55. European Pharmacopoeia 5.2.6. Evaluation of Safety of Veterinary Vaccines and Immunosera. 6th ed. Strasbourg, France; European Department for the Quality of Medicine within the Council of Europe.
56. European Pharmacopoeia 5.2.9. Evaluation of Safety of Each Batch of Veterinary Vaccines and Immunosera. 6th ed. Strasbourg, France; European Department for the Quality of Medicine within the Council of Europe.
57. Weisser K, Hechler U. Animal welfare aspects in the quality control of immunobiologicals. A critical evaluation of animal tests in pharmacopoeial monographs. Nottingham, UK, FRAME for ECVAM and the Paul-Ehrlich-Institute, 1997.
58. Cussler K, Possnecker A. Is there still a need for the target animal safety test beyond 2000? Pharmeuropa Special Issue, Proceedings Biologicals Beyond 2000. 2000;00:343-347.
59. AGAATI 2000.
60. VCB Notice 05.01.
61. European Pharmacopoeia Monograph 04/2008:0216. Rabies Vaccine for Human Use Prepared in Cell Culture. 6th ed. Strasbourg, France; European Department for the Quality of Medicine within the Council of Europe. 2008.
62. Leung T, Corran PH, Gee C, Ekong TAN, Sesardic D. Application of an in vitro endopeptidase assay for detection of residual toxin activity in tetanus toxoids. Brown F, Hendriksen C, Sesardic D, Cussler K, editors. In: Advancing Science and Elimination of the Use of Laboratory Animals for Development and Control of Vaccines and Hormones. Basel, Karger, Dev Biol 2002;111:327-332.
63. International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Products (VICH): GL 41; TARGET ANIMAL SAFETY: EXAMINATION OF LIVE VETERINARY VACCINES IN TARGET ANIMALS FOR ABSENCE OF REVERSION TO VIRULENCE. 2007. Available at: http://www.vichsec.org/en/guidelines2.htm.
64. International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Products (VICH): GL 44; Target Animal Safety for Veterinary Live and Inactivated vaccines. 2008. Available at: http://www.vichsec.org/en/guidelines2.htm.
65. International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Products Guidelines; Available at: http://www.vichsec.org/en/guidelines2.htm.